SHARPIN is an endogenous inhibitor of β1-integrin activation
Juha Rantala(Keskuslaboratorio), Johanna Ivaska(University of Turku), John P. Sundberg(Jackson Laboratory), Maddy Parsons(King's College London), Elina Mattila(Tampere University Hospital), Olli Kallioniemi(University of Helsinki), Christopher J. Potter(Johns Hopkins University), Stefan Veltel(University of Turku), Janet A. Askari(Wellcome Centre for Cell-Matrix Research), Jeroen Pouwels(University of Helsinki), Marko Salmi(University of Turku), Petra Laasola(VTT Technical Research Centre of Finland), Martin J. Humphries(Wellcome Centre for Cell-Matrix Research), Ted Duffy(Jackson Laboratory), Teijo Pellinen(University of Helsinki)
Cited by 200
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Integrin ligands at a glance
|Journal of Cell Science|2006|1.7k
Integrin Structure, Activation, and Interactions
|Cold Spring Harbor Perspectives in Biology|2011|1.2k
Vinculin controls focal adhesion formation by direct interactions with talin and actin
|The Journal of Cell Biology|2007|916
Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.
|The Journal of Cell Biology|1989|793